Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci - PubMed (original) (raw)
. 2011 Dec;70(6):897-912.
doi: 10.1002/ana.22609.
Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium; Federica Esposito, Joachim Reischl, Stephan Lehr, David Bauer, Jürgen Heubach, Rupert Sandbrink, Christoph Pohl, Gilles Edan, Ludwig Kappos, David Miller, Javier Montalbán, Chris H Polman, Mark S Freedman, Hans-Peter Hartung, Barry G W Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Douglas S Goodin, Douglas Jeffery, Paul O'Connor, George C Ebers, Dawn Langdon, Anthony T Reder, Anthony Traboulsee, Frauke Zipp, Sebastian Schimrigk, Jan Hillert, Melanie Bahlo, David R Booth, Simon Broadley, Matthew A Brown, Brian L Browning, Sharon R Browning, Helmut Butzkueven, William M Carroll, Caron Chapman, Simon J Foote, Lyn Griffiths, Allan G Kermode, Trevor J Kilpatrick, Jeanette Lechner-Scott, Mark Marriott, Deborah Mason, Pablo Moscato, Robert N Heard, Michael P Pender, Victoria M Perreau, Devindri Perera, Justin P Rubio, Rodney J Scott, Mark Slee, Jim Stankovich, Graeme J Stewart, Bruce V Taylor, Niall Tubridy, Ernest Willoughby, James Wiley, Paul Matthews, Filippo M Boneschi, Alastair Compston, Jonathan Haines, Stephen L Hauser, Jacob McCauley, Adrian Ivinson, Jorge R Oksenberg, Margaret Pericak-Vance, Stephen J Sawcer, Philip L De Jager, David A Hafler, Paul I W de Bakker
Affiliations
- PMID: 22190364
- PMCID: PMC3247076
- DOI: 10.1002/ana.22609
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci
Nikolaos A Patsopoulos et al. Ann Neurol. 2011 Dec.
Erratum in
- Ann Neurol. 2013 Apr;73(4):561
Abstract
Objective: To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci.
Methods: We synthesized 7 MS GWAS. Each data set was imputed using HapMap phase II, and a per single nucleotide polymorphism (SNP) meta-analysis was performed across the 7 data sets. We explored RNA expression data using a quantitative trait analysis in peripheral blood mononuclear cells (PBMCs) of 228 subjects with demyelinating disease.
Results: We meta-analyzed 2,529,394 unique SNPs in 5,545 cases and 12,153 controls. We identified 3 novel susceptibility alleles: rs170934(T) at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10(-8)) near EOMES, rs2150702(G) in the second intron of MLANA on chromosome 9p24.1 (OR, 1.16; p = 3.3 × 10(-8)), and rs6718520(A) in an intergenic region on chromosome 2p21, with THADA as the nearest flanking gene (OR, 1.17; p = 3.4 × 10(-8)). The 3 new loci do not have a strong cis effect on RNA expression in PBMCs. Ten other susceptibility loci had a suggestive p < 1 × 10(-6) , some of these loci have evidence of association in other inflammatory diseases (ie, IL12B, TAGAP, PLEK, and ZMIZ1).
Interpretation: We have performed a meta-analysis of GWAS in MS that more than doubles the size of previous gene discovery efforts and highlights 3 novel MS susceptibility loci. These and additional loci with suggestive evidence of association are excellent candidates for further investigations to refine and validate their role in the genetic architecture of MS.
Copyright © 2011 American Neurological Association.
Figures
Figure 1. Manhattan plot for the meta-analysis genome-wide – log(p-values) (fixed effects)
X axis displays the 22 autosomal chromosomes and Y axis the –log(p-values) per SNP. The red line represents the genome-wide significance level (5×10−8)
Figure 2. Regional association plots for the newly identified genome-wide significant loci and respective forest plots
(A, B) rs170934 in EOMES, (C, D) rs2150702 in MLANA, and (E, F) rs6718520 near THADA. Regional plots: The X axis plots 1 million basepairs around the most statistically significant (index) SNP, which is highlighted by a large red diamond. r2 of a given SNP with the index SNP is illustrated with the intensity of the red color. The blue line represents the recombination rate. Each square represents one SNP. Forest Plots: The per-datasets’ weights are from the fixed effects meta-analysis. The p-value is for the Cohran’s Q test for statistical heterogeneity. INFO score is an imputation quality metric, corresponding to the ratio of observed vs. expected allele frequency. Values greater of 0.8 indicate high imputation quality. Genotyped SNPs have a value of 1. SNPs that were genotyped in a given dataset are marked with an asterisk.
Figure 3. Overlap of the genetic architecture of MS with that of other inflammatory diseases
(A) Percentage of non-MHC genome-wide significant (P<5×10−8) SNPs of inflammatory diseases that are non-statistically significant (NS), or significant in the same direction (SD) or the opposite direction (OD) in the current MS meta-analysis. CE: celiac disease, CD: Crohn’s disease, UC: ulcerative colitis, IBD: inflammatory bowel diseases (CD+UC), PSO: psoriasis, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, T1D: type 1 diabetes, T2D: type 2 diabetes, HE: height, LI: lipids, MI: myocardial infraction. NS: non-statistically significant, OD: opposite direction of effects, SD: same direction of effects. (B) Regional association plot for the TAGAP gene. All SNPs report –lop(p-values) from the MS meta-analysis, besides the 3 ones indicated by the respective disease names. The p-values reported for these 3 SNPs come from the respective original publications. The T1D and CE SNP is rs1738074, whereas the RA one is rs212389.
Comment in
- Decoding multiple sclerosis.
Oksenberg JR, Hauser SL. Oksenberg JR, et al. Ann Neurol. 2011 Dec;70(6):A5-7. doi: 10.1002/ana.22680. Ann Neurol. 2011. PMID: 22190375 No abstract available.
Similar articles
- Variant of EOMES Associated with Increasing Risk in Chinese Patients with Relapsing-remitting Multiple Sclerosis.
Chen S, Zhang J, Liu QB, Zhuang JC, Wu L, Xu YF, Li HF, Wu ZY, Xiao BG. Chen S, et al. Chin Med J (Engl). 2018 Mar 20;131(6):643-647. doi: 10.4103/0366-6999.226892. Chin Med J (Engl). 2018. PMID: 29521285 Free PMC article. - Replication study of GWAS risk loci in Greek multiple sclerosis patients.
Hadjigeorgiou GM, Kountra PM, Koutsis G, Tsimourtou V, Siokas V, Dardioti M, Rikos D, Marogianni C, Aloizou AM, Karadima G, Ralli S, Grigoriadis N, Bogdanos D, Panas M, Dardiotis E. Hadjigeorgiou GM, et al. Neurol Sci. 2019 Feb;40(2):253-260. doi: 10.1007/s10072-018-3617-6. Epub 2018 Oct 26. Neurol Sci. 2019. PMID: 30361804 - A variant on chromosome 2p13.3 is associated with atopic dermatitis in Chinese Han population.
Cai XY, Zheng XD, Fang L, Zhou FS, Sheng YJ, Wu YY, Yu CX, Zhu J, Xiao FL. Cai XY, et al. Gene. 2017 Sep 10;628:281-285. doi: 10.1016/j.gene.2017.07.059. Epub 2017 Jul 21. Gene. 2017. PMID: 28739399 - Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.
Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, Debrus S, Raelson JV, Tejasvi T, Belouchi M, West SL, Barker JN, Kõks S, Kingo K, Balschun T, Palmieri O, Annese V, Gieger C, Wichmann HE, Kabesch M, Trembath RC, Mathew CG, Abecasis GR, Weidinger S, Nikolaus S, Schreiber S, Elder JT, Weichenthal M, Nothnagel M, Franke A. Ellinghaus D, et al. Am J Hum Genet. 2012 Apr 6;90(4):636-47. doi: 10.1016/j.ajhg.2012.02.020. Am J Hum Genet. 2012. PMID: 22482804 Free PMC article. - MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene.
Nischwitz S, Wolf C, Andlauer TF, Czamara D, Zettl UK, Rieckmann P, Buck D, Ising M, Bettecken T, Mueller-Myhsok B, Weber F. Nischwitz S, et al. J Neuroimmunol. 2015 Feb 15;279:46-9. doi: 10.1016/j.jneuroim.2015.01.008. Epub 2015 Jan 23. J Neuroimmunol. 2015. PMID: 25670000
Cited by
- The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
Bebo BF Jr, Banwell BL, Whitacre CC, Coetzee T, Dalgas U, De Jager PL, Proebstel AK, Yong VW, Benveniste EN, Thompson AJ. Bebo BF Jr, et al. Mult Scler. 2024 Sep;30(10):1242-1251. doi: 10.1177/13524585241266483. Epub 2024 Aug 30. Mult Scler. 2024. PMID: 39212108 Free PMC article. - Adaptive and Innate Immunity Are Key Drivers of Age at Onset of Multiple Sclerosis.
Misicka E, Huang Y, Loomis S, Sadhu N, Fisher E, Gafson A, Runz H, Tsai E, Jia X, Herman A, Bronson PG, Bhangale T, Briggs FB. Misicka E, et al. Neurol Genet. 2024 May 29;10(3):e200159. doi: 10.1212/NXG.0000000000200159. eCollection 2024 Jun. Neurol Genet. 2024. PMID: 38817245 Free PMC article. - Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease.
Hawiger D. Hawiger D. Front Aging Neurosci. 2024 Feb 16;16:1350240. doi: 10.3389/fnagi.2024.1350240. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38435400 Free PMC article. Review. - Identification of key genes as potential diagnostic and therapeutic targets for comorbidity of myasthenia gravis and COVID-19.
Huang L, Zuo Y, Yang H, He X, Zhang L. Huang L, et al. Front Neurol. 2024 Feb 7;14:1334131. doi: 10.3389/fneur.2023.1334131. eCollection 2023. Front Neurol. 2024. PMID: 38384322 Free PMC article. - Circular RNA in Multiple Sclerosis: Pathogenicity and Potential Biomarker Development: A Systematic Review.
Mohammed EM. Mohammed EM. Epigenet Insights. 2023 Nov 29;16:25168657231213195. doi: 10.1177/25168657231213195. eCollection 2023. Epigenet Insights. 2023. PMID: 38033465 Free PMC article. Review.
References
- Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61–76. - PubMed
- Hafler DA, Compston A, et al. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–62. - PubMed
- The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–828. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 MH46276/MH/NIMH NIH HHS/United States
- R01 HG004960/HG/NHGRI NIH HHS/United States
- U01 MH79470/MH/NIMH NIH HHS/United States
- R01 MH59586/MH/NIMH NIH HHS/United States
- R01 MH59587/MH/NIMH NIH HHS/United States
- R01 NS067305/NS/NINDS NIH HHS/United States
- R01 MH59565/MH/NIMH NIH HHS/United States
- R01 MH61675/MH/NIMH NIH HHS/United States
- R01 MH59571/MH/NIMH NIH HHS/United States
- U01 MH79469/MH/NIMH NIH HHS/United States
- G0000934/MRC_/Medical Research Council/United Kingdom
- R01 MH67257/MH/NIMH NIH HHS/United States
- U01 MH46318/MH/NIMH NIH HHS/United States
- R01 MH60870/MH/NIMH NIH HHS/United States
- RC2 NS070340-01/NS/NINDS NIH HHS/United States
- R01 MH60879/MH/NIMH NIH HHS/United States
- R01 MH59566/MH/NIMH NIH HHS/United States
- R01MH81800/MH/NIMH NIH HHS/United States
- RC2 NS070340/NS/NINDS NIH HHS/United States
- R01 MH59588/MH/NIMH NIH HHS/United States
- 068545/Z/02/WT_/Wellcome Trust/United Kingdom
- P01 AI039671/AI/NIAID NIH HHS/United States
- U01 MH46289/MH/NIMH NIH HHS/United States
- R01 NS067305-01/NS/NINDS NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical